Paeds Vivas · gastroenterology-hepatology-and-nutrition
Chronic liver disease, cirrhosis and portal hypertension: Viva
Branching clinical structured oral on chronic liver disease, cirrhosis and portal hypertension in children: recognising the presentation of portal hypertension, the classification of causes, the acute variceal bleeding management bundle, primary prophylaxis, spontaneous bacterial peritonitis, and hepatopulmonary syndrome.
On this page & tools
Target exams
Branch 1: Assessing portal hypertension
The candidate should recognise that a child with biliary atresia and a Kasai portoenterostomy is at high risk for progressive fibrosis and portal hypertension, and that the thrombocytopenia of 78,000 per cubic millimetre is a strong clue to clinically significant portal hypertension from hypersplenism. The key is to interpret the platelet count not as an isolated abnormality but as a marker of splenic sequestration from portal venous congestion. [1]
A strong candidate would explain that the hepatic venous pressure gradient of 10 mmHg or more defines clinically significant portal hypertension, which is the threshold at which varices form and the risk of bleeding becomes real. The candidate should describe the focused examination looking for splenomegaly, ascites with shifting dullness, spider naevi, palmar erythema, and signs of chronic liver disease, and should request an abdominal ultrasound with Doppler to assess portal vein patency, flow direction, splenomegaly, and the presence of collaterals. [1]
If the examiner presses on the next step, the candidate should name upper gastrointestinal endoscopy as the gold standard for diagnosing and characterising varices, and should explain that the finding of large varices or red wale signs would prompt consideration of primary prophylaxis with either non-selective beta-blockers or endoscopic variceal ligation. [1]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References3Show ledgerHide ledger
- [1]de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, et al Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022.PMID 35120736
- [2]Cifuentes LI, Gattini D, Torres-Robles R, Gana JC Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database Syst Rev, 2021.PMID 33498095
- [3]Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, et al International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation, 2016.PMID 27326810